Acrux completes Phase I trial of testosterone lotion
Wednesday, 06 October, 2004
Acrux (ASX: ACR) has completed a Phase I clinical trial of its testosterone metered-dose lotion for the treatment of hypogonadism, or low testosterone, in men.
The proof-of-concept study compared Acrux's product with the current market leader, a commercially available testosterone gel in five men with low testosterone. The trial was performed at Prince Henry's Institute of Medical Research in Melbourne, and was sponsored by Acrux subsidiary Acrux DDS.
The company will now seek advice on the appropriate regulatory path for approval in major world markets including the US, CEO Igor Gonda said.
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
